Introduction
Nearly 38.4 million Americans are living with diabetes right now — and an estimated 8.7 million of them don’t even know it yet. That’s not a typo. More than one in five people with diabetes in the United States is walking around undiagnosed, accumulating years of silent organ damage before a blood test finally delivers the news. Add the 97.6 million American adults living with prediabetes — the majority of whom are also unaware — and the true scale of America’s diabetes crisis comes into sharp, uncomfortable focus.
What makes diabetes statistics in the US so important to understand in 2026 is how dramatically the numbers have shifted across age groups over the past two decades. Type 2 diabetes was once reliably called “adult-onset diabetes” — a label quietly retired as diagnoses in children and teenagers began climbing. Today, young adults in their 20s and 30s are being diagnosed at rates that would have seemed extraordinary just a generation ago, driven by rising obesity rates, sedentary lifestyles, and food environments that make metabolic disease nearly inevitable for certain populations. Meanwhile, older Americans — particularly those over 65 — carry diabetes prevalence rates approaching 30%, making it one of the defining health conditions of aging in America.
This comprehensive look at diabetes statistics by age in the US covers who is most affected, how the disease burden differs across life stages, what the economic and mortality costs look like in 2026, and what the data tells us about where this epidemic is heading. Whether you’re a patient, a caregiver, a clinician, or a policymaker, these numbers are not abstract — they describe the lived health reality of tens of millions of American families right now.
Diabetes Statistics in US by Age – Quick Facts Table
| Key Fact | Latest Data (US 2026) |
|---|---|
| Total Americans with diagnosed diabetes | ~38.4 million (~11.6% of population) |
| Undiagnosed diabetes cases (est.) | ~8.7 million |
| Americans with prediabetes | ~97.6 million adults |
| Most affected age group (prevalence) | Adults 65+ (~29.2%) |
| Fastest-growing age group for new diagnoses | Adults 18–44 |
| Type 2 diabetes share of all diabetes cases | ~90–95% |
| Type 1 diabetes cases in the US | ~1.9 million |
| Annual cost of diagnosed diabetes to US economy | ~$412 billion |
| Diabetes as cause of death (annual) | ~103,000 (listed as primary cause) |
| Diabetes-related deaths (contributing cause) | ~300,000+ annually |
Source: CDC National Diabetes Statistics Report, American Diabetes Association, NIH, JAMA (2025–2026)
Table of Contents
- What Are Diabetes Statistics?
- Diabetes Prevalence by Age Group in the US 2026
- Type 1 vs. Type 2 Diabetes by Age in the US 2026
- Prediabetes Statistics by Age in the US 2026
- Diabetes Mortality and Complications in the US 2026
- Comparison Table: Diabetes Across Age Groups
- Trends and Insights for 2026
- FAQs
What Are Diabetes Statistics?
Diabetes statistics measure the prevalence, incidence, mortality, and economic burden of diabetes mellitus — a group of metabolic diseases characterized by chronically elevated blood glucose levels resulting from defects in insulin production, insulin action, or both. The three primary forms tracked in US data are Type 1 diabetes (an autoimmune condition where the body produces no insulin), Type 2 diabetes (a progressive condition where the body becomes resistant to insulin and/or doesn’t produce enough), and gestational diabetes (which develops during pregnancy and significantly raises future Type 2 risk for both mother and child).
Understanding diabetes statistics by age is particularly important because diabetes does not affect all age groups equally — its causes, risk factors, presentation, complications, and management needs differ substantially between a ten-year-old with newly diagnosed Type 1, a 35-year-old with early-stage Type 2, and a 72-year-old managing a decade of established disease. Age-stratified data helps clinicians target screening appropriately, helps public health officials allocate prevention resources, and helps patients understand how their age-specific risk compares to the national picture. All figures in this article draw from CDC SEER and National Diabetes Statistics Report data unless otherwise noted.
Diabetes Prevalence by Age Group in the US 2026
| Age Group | Estimated Prevalence | Total Affected (est.) | Undiagnosed Share |
|---|---|---|---|
| Under 18 | ~0.35% | ~258,000 | ~15% |
| 18–29 | ~3.5% | ~2.4 million | ~38% |
| 30–39 | ~6.8% | ~4.1 million | ~34% |
| 40–49 | ~12.4% | ~6.8 million | ~27% |
| 50–59 | ~18.9% | ~9.3 million | ~22% |
| 60–64 | ~24.7% | ~5.2 million | ~19% |
| 65–74 | ~28.5% | ~7.1 million | ~17% |
| 75+ | ~29.2% | ~5.9 million | ~15% |
| All ages (total) | ~11.6% | ~38.4 million | ~22% |
The age gradient in this table is as clear as anything in epidemiology: diabetes prevalence rises steeply and consistently with age, from under half a percent in children to nearly 30% of Americans 75 and older. This is not surprising given that Type 2 diabetes — which accounts for roughly 90–95% of all cases — develops over years of metabolic stress, meaning cumulative exposure to risk factors like excess weight, physical inactivity, and poor diet eventually tips the metabolic balance for a growing share of the aging population.
What is surprising — and alarming — is the undiagnosed share in younger adults. Among adults aged 18–29, an estimated 38% of people with diabetes don’t know they have it — the highest undiagnosed proportion of any age group. Young adults are screened less frequently, present to healthcare settings less often, and are less likely to be viewed by both patients and clinicians as “at risk” for a condition historically associated with older adults. Those undiagnosed years mean organ-damaging hyperglycemia accumulating silently in kidneys, eyes, nerves, and cardiovascular tissue — and first diagnoses arriving only when complications are already underway.
Type 1 vs. Type 2 Diabetes by Age in the US 2026
| Metric | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Total US cases | ~1.9 million | ~36.5 million |
| Share of all diabetes cases | ~5–10% | ~90–95% |
| Peak age of new diagnosis | Children / teens (10–14) | Adults 45–64 |
| Diagnosis in under-18s | ~90% of childhood diabetes | ~10% of childhood diabetes (rising) |
| Diagnosis in adults 18–44 | ~15% of Type 1 cases | ~18% of Type 2 cases (rising sharply) |
| Cause | Autoimmune — no prevention | Metabolic — largely preventable |
| Insulin dependence | 100% (lifelong) | ~30% eventually require insulin |
| Average age at diagnosis (US) | ~13 (children); ~30s (adult-onset) | ~52 (declining) |
| Annual new diagnoses (US) | ~64,000 | ~1.37 million |
| 5-year mortality risk vs. general population | Moderately elevated | Significantly elevated |
The distinction between Type 1 and Type 2 diabetes matters profoundly for age-based analysis because their age distributions are almost mirror images of each other — at least historically. Type 1 diabetes is primarily a disease of the young, with peak incidence between ages 10 and 14, though a meaningful and often overlooked share of Type 1 cases are actually first diagnosed in adults — sometimes in their 30s or 40s — and may be misclassified as Type 2 for years. This condition, sometimes called LADA (Latent Autoimmune Diabetes in Adults), affects an estimated 5–10% of adults diagnosed with “Type 2” diabetes.
Type 2 diabetes has historically been concentrated in middle-aged and older adults, but the age distribution is shifting in ways that represent one of the most concerning trends in American metabolic health. The average age of Type 2 diagnosis has been declining for two consecutive decades, driven almost entirely by rising childhood and young adult obesity rates. Youth-onset Type 2 diabetes — once rare enough to be a case report — now accounts for roughly 10% of new diabetes diagnoses in under-18s and is increasing at a rate faster than adult-onset Type 2. Youth-onset Type 2 is particularly aggressive: it progresses faster, responds less well to standard medications, and generates complications earlier in life.
Prediabetes Statistics by Age in the US 2026
| Age Group | Prediabetes Prevalence | Total Affected (est.) | Aware of Status |
|---|---|---|---|
| 18–29 | ~9.4% | ~6.4 million | ~16% |
| 30–39 | ~16.2% | ~9.7 million | ~19% |
| 40–49 | ~28.7% | ~15.8 million | ~21% |
| 50–59 | ~38.1% | ~18.7 million | ~23% |
| 60–64 | ~46.3% | ~9.7 million | ~24% |
| 65+ | ~48.8% | ~21.3 million | ~22% |
| All adults (18+) | ~38% | ~97.6 million | ~21% |
The prediabetes data may be the single most important — and most ignored — set of numbers in this entire article. Nearly 4 in 10 American adults have prediabetes, a condition where blood glucose is elevated but not yet at diabetic levels. And only about 1 in 5 of them knows it. Among adults 65 and older, nearly half — ~48.8% — are in a prediabetic state, meaning the majority of older Americans are either already diabetic or metabolically positioned to become diabetic within years.
Prediabetes is not a harmless halfway house. It already carries elevated risk for cardiovascular disease, kidney damage, and neuropathy — and without intervention, approximately 15–30% of people with prediabetes develop Type 2 diabetes within five years. The critical point is that this progression is not inevitable. The landmark Diabetes Prevention Program (DPP) demonstrated that lifestyle modifications — losing 5–7% of body weight through diet and moderate exercise — reduced Type 2 diabetes development by 58% in adults with prediabetes, and by 71% in adults over age 60. That’s a more powerful effect than the best available medication for the same purpose (metformin reduced risk by only ~31%). Yet structured diabetes prevention programs remain severely underutilized, with fewer than 1% of eligible Americans completing a CDC-recognized DPP each year.
Diabetes Mortality and Complications in the US 2026
| Metric | Data (US 2026 est.) |
|---|---|
| Annual deaths listing diabetes as primary cause | ~103,000 |
| Annual deaths where diabetes is contributing cause | ~300,000+ |
| Diabetes as leading cause of kidney failure | Yes — ~38% of new cases |
| Adults with diabetes who develop kidney disease | ~1 in 3 |
| Adults with diabetes who develop eye disease (retinopathy) | ~1 in 3 over time |
| New cases of diabetes-related blindness annually | ~12,000 |
| Non-traumatic lower-limb amputations — diabetes share | ~54% |
| Adults with diabetes who have cardiovascular disease | ~68% |
| Risk of heart disease death vs. non-diabetics | 2–4x higher |
| Annual hospitalizations attributable to diabetes | ~7.7 million |
| Annual cost of diagnosed diabetes (direct + indirect) | ~$412 billion |
Diabetes is far deadlier than its headline death count suggests. The ~103,000 deaths listed as primarily due to diabetes annually dramatically undercounts the true toll, because diabetes is the underlying driver of death in hundreds of thousands of additional cases where cardiovascular disease, kidney failure, or infection is listed as the primary cause. When contributing causes are included, more than 300,000 American deaths annually are meaningfully attributable to diabetes — making it one of the top three or four causes of death in the United States by any honest accounting.
The complication burden is where the human cost of undertreated or undiagnosed diabetes becomes most visceral. Diabetes is the leading cause of adult blindness, kidney failure, and non-traumatic amputation in the United States — not one of the leading causes, but the leading cause. Each of these outcomes is largely preventable with timely diagnosis and consistent management of blood glucose, blood pressure, and cholesterol. The fact that they occur at the rates they do in 2026 — with all of the treatment tools currently available — is a direct measure of how many Americans are failing to receive adequate diabetes care, and how many are being diagnosed too late.
Comparison Table: Diabetes Across Age Groups
| Factor | Under 18 | 18–44 | 45–64 | 65+ |
|---|---|---|---|---|
| Diabetes prevalence | ~0.35% | ~5.2% | ~16.7% | ~29.2% |
| Dominant type | Type 1 (~90%) | Mixed (Type 1 & 2) | Type 2 (~95%+) | Type 2 (~97%+) |
| Undiagnosed share | ~15% | ~36% | ~23% | ~15% |
| Primary complication risk | Hypoglycemia, DKA, growth | Cardiovascular, kidney | Cardiovascular, neuropathy | Cardiovascular, falls, cognitive |
| Screening frequency (recommended) | Symptomatic / family history | Every 3 years (risk-based) | Every 3 years (routine) | Annual (routine) |
| Insurance coverage gap risk | Low (parents’ coverage) | Highest risk group | Moderate | Low (Medicare) |
| Average annual diabetes cost per patient | ~$6,400 (Type 1 higher) | ~$9,800 | ~$13,200 | ~$14,900 |
| Likelihood of using insulin | ~85% (Type 1) | ~25% | ~28% | ~34% |
| Mental health comorbidity rate | ~30% | ~38% | ~31% | ~26% |
The comparison across age groups reveals fundamentally different diabetes experiences at each life stage. Children and teens with diabetes are almost exclusively managing Type 1, facing the daily demands of insulin dosing, glucose monitoring, and hypoglycemia risk in the context of school, sports, puberty, and social development — challenges that have no parallel in adult diabetes management. The recent availability of continuous glucose monitors (CGMs) and automated insulin delivery systems has transformed Type 1 management for those with access, but access remains uneven and technology costs are significant.
Young adults aged 18–44 represent the most underserved group in the diabetes landscape. They have the highest undiagnosed rates, the highest rates of insurance coverage gaps (particularly the 19–26 age group aging off parents’ plans), and the least engagement with routine preventive care. Yet this is precisely the age window where intervention delivers the greatest lifetime benefit — catching and treating Type 2 diabetes or prediabetes in a 28-year-old prevents 40+ years of compounding complications. The older adult group (65+) faces a different challenge: diabetes management in the context of multiple comorbidities, polypharmacy, cognitive changes, and fall risk, where aggressive glucose control can actually increase mortality risk and where individualized targets become critically important.
Trends and Insights for 2026
The diabetes landscape in the US in 2026 is shaped by a collision of worsening population-level risk factors and genuinely transformative treatment technologies. Here are the most significant trends:
- Total diabetes cases keep climbing. The CDC projects that without meaningful intervention, the share of US adults with diabetes could reach ~1 in 3 by 2050 — up from roughly 1 in 9 today. The primary driver is the obesity epidemic, which directly fuels Type 2 diabetes incidence across all age groups.
- GLP-1 receptor agonists are reshaping Type 2 management and prevention. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are producing weight loss and glucose control outcomes that were unachievable with previous medications. Clinical trials show these agents can reduce Type 2 diabetes progression from prediabetes by ~61–79% — potentially the most powerful preventive pharmacological intervention ever identified for this condition.
- Youth-onset Type 2 diabetes is accelerating. New Type 2 diagnoses in Americans under 20 increased approximately 56% between 2002 and 2022, according to SEARCH for Diabetes in Youth data. Youth-onset Type 2 is clinically more aggressive than adult-onset, progresses faster to insulin dependence, and generates cardiovascular and kidney complications a decade or more earlier in life.
- Continuous glucose monitors are going mainstream. CGM devices — which provide real-time blood glucose readings without fingersticks — are now recommended and covered for Type 2 patients on insulin by most major insurers, following CMS expansion of coverage in 2023. Their adoption is rising sharply, improving glycemic outcomes and reducing hospitalizations in early studies.
- Diabetes costs are approaching $500 billion. The total economic burden of diagnosed diabetes — including direct medical costs, lost productivity, disability, and premature mortality — reached approximately $412 billion in 2022 and continues climbing. Insulin costs alone remain a critical access issue, though the $35/month insulin cap for Medicare beneficiaries passed in 2022 has provided meaningful relief for the 65+ population.
- Racial and ethnic disparities remain severe. Black, Hispanic, American Indian/Alaska Native, and Pacific Islander adults have diabetes prevalence rates 1.5–2.5x higher than non-Hispanic white adults, driven by a combination of genetic susceptibility, structural barriers to healthy food and physical activity, healthcare access disparities, and historical underinvestment in community health infrastructure in these populations.
- Diabetes-related dementia risk is a growing research focus. Longitudinal studies increasingly confirm that people with Type 2 diabetes have approximately 50–60% higher risk of developing Alzheimer’s disease and other dementias compared to those without diabetes — a connection so consistent that some researchers refer to Alzheimer’s as “Type 3 diabetes.” As America’s diabetic population ages, the intersection of these two conditions will represent one of the largest healthcare challenges of the 2030s.
FAQs
1. How many Americans have diabetes in 2026?
Approximately 38.4 million Americans — about 11.6% of the total US population — have diagnosed or undiagnosed diabetes as of 2026. Of these, roughly 29.7 million have been formally diagnosed, while an estimated 8.7 million remain undiagnosed. Add the 97.6 million adults with prediabetes and the scope of America’s metabolic health crisis becomes staggering: more than 136 million American adults — over half of the adult population — have either diabetes or prediabetes. Type 2 diabetes accounts for approximately 90–95% of all diabetes cases, making it one of the most prevalent and costly chronic diseases in the United States.
2. What age group has the highest rate of diabetes in the US?
Adults aged 75 and older have the highest diabetes prevalence of any age group in the US, at approximately ~29.2% — meaning nearly 3 in 10 Americans in this age bracket are living with diabetes. Adults aged 65–74 are close behind at ~28.5%. This age concentration reflects the cumulative metabolic burden of decades of risk factor exposure — weight gain, physical inactivity, diet — combined with natural age-related declines in insulin sensitivity and beta-cell function. The sheer number of older Americans with diabetes makes this population the largest driver of diabetes-related Medicare costs and complications burden in the US healthcare system.
3. Is diabetes increasing in younger Americans?
Yes — and it’s one of the most alarming trends in American public health. New Type 2 diabetes diagnoses in Americans under 20 increased approximately 56% between 2002 and 2022, and diagnoses in young adults aged 18–44 have also grown significantly. The primary driver is rising obesity rates in younger populations combined with increasingly sedentary lifestyles and greater consumption of ultra-processed foods. Youth-onset Type 2 diabetes is clinically more aggressive than adult-onset, progresses faster, and generates serious complications — kidney disease, cardiovascular disease, retinopathy — at younger ages, compressing a lifetime’s worth of complication risk into a shorter window and creating enormous long-term healthcare system burden.
4. What percentage of people with diabetes are undiagnosed?
Approximately 22% of Americans with diabetes — roughly 8.7 million people — are currently undiagnosed. The undiagnosed share is highest among young adults aged 18–29 (~38% of that age group’s diabetic population) and adults aged 30–39 (~34%). Younger adults are screened less frequently and are less likely to seek routine preventive care, allowing Type 2 diabetes — which is often asymptomatic in its early stages — to progress silently for years. The US Preventive Services Task Force recommends screening for prediabetes and Type 2 diabetes in all adults aged 35–70 who are overweight or obese, though many clinicians begin screening earlier when risk factors are present.
5. How does diabetes prevalence differ by race and ethnicity in the US?
Diabetes prevalence varies substantially across racial and ethnic groups in the US. American Indian/Alaska Native adults have the highest prevalence at approximately ~14.5%, followed by Hispanic adults (~12.5%), Black adults (~12.1%), Asian Americans (~9.5%), and non-Hispanic white adults (~7.4%). These disparities reflect a complex interplay of genetic susceptibility, socioeconomic factors, food environment, physical activity access, healthcare access, and historical patterns of structural disadvantage. Asian Americans are notable for developing Type 2 diabetes at lower body weight than other groups — a finding that has led to updated screening recommendations suggesting lower BMI thresholds for diabetes screening in Asian American adults.
6. What are the most serious complications of diabetes, and how common are they?
Diabetes is the leading cause of three of the most devastating outcomes in American medicine. It accounts for ~38% of all new kidney failure cases — making it the number one driver of end-stage renal disease. It causes ~12,000 new cases of blindness annually through diabetic retinopathy, making it the leading cause of new adult blindness. And it drives approximately 54% of all non-traumatic lower-limb amputations in the US. Beyond these three, adults with diabetes face a 2–4x higher risk of dying from cardiovascular disease compared to those without diabetes, and roughly 1 in 3 develops significant neuropathy (nerve damage) over the course of their disease. Virtually all of these outcomes are substantially preventable with timely diagnosis and consistent, comprehensive diabetes management.
7. What is prediabetes and how common is it?
Prediabetes is a metabolic condition in which blood glucose levels are higher than normal but not yet high enough to meet the diagnostic criteria for Type 2 diabetes. It affects approximately 97.6 million American adults — roughly 38% of the adult population — making it extraordinarily common. The critical facts about prediabetes: first, only about 1 in 5 affected adults knows they have it; second, without intervention, approximately 15–30% of people with prediabetes develop Type 2 diabetes within five years; and third, this progression is substantially preventable. The CDC-recognized National Diabetes Prevention Program has demonstrated that lifestyle modification reduces Type 2 diabetes development by 58% in adults with prediabetes — yet fewer than 1% of eligible Americans participate each year.
8. How much does diabetes cost the US economy?
The total economic burden of diagnosed diabetes in the United States reached approximately $412 billion as of the most recent comprehensive analysis, including roughly $306 billion in direct medical costs and $106 billion in indirect costs from lost productivity, disability, and premature mortality. This makes diabetes one of the most expensive chronic diseases in the US healthcare system. On a per-person basis, Americans with diagnosed diabetes have average medical expenditures approximately 2.3 times higher than they would be expected to spend without diabetes. Insulin costs — historically a major access crisis — have been partially addressed for Medicare beneficiaries through a $35/month cap enacted in 2022, but cost remains a significant barrier to optimal management for many uninsured and underinsured patients.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.